Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, shared a post on X about a paper by Fei Zhou et al. published in Nature Reviews Clinical Oncology:
“EGFR-mutant NSCLC is evolving.
EGFR TKIs now cover early-stage and locally advanced disease, a milestone in precision oncology.
New combos with anti-angiogenics, chemo, ADCs and bispecifics aim to boost OS.”
“The changing treatment landscape of EGFR-mutant non-small-cell lung cancer”
Authors: Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel Tan, Suresh Ramalingam and Caicun Zhou.
More posts featuring Diego Díaz García.
